News
In a Collaboration Initiated by a Sheba Physician, Medical Researchers from More Than 130 Countries Are Working Together to Study Retinoblastoma
Global Medical Collaboration Spearheaded by a Sheba Physician Serves to Advance Knowledge of Retinoblastoma: Read more here:
Read More
Sheba Medical Center and Israeli Medical Technology Company Nucleai Partner to Accelerate AI Powered Drug Discovery and Clinical Testing
New Sheba and Nucleai Partnership is Set to Revolutionize Drug Development and Clinical Testing
Read More
New Hope from Israel: Data Suggests Vaccines Will Empty COVID-19 Wards
According to New Israeli Data, Only One in 1,500 of Those Fully Vaccinated Contracted COVID-19. Click Here to Learn More:
Read More
New Sheba Study Indicates That Low Free Triiodothyronine Levels Are Associated with Higher COVID-19 Mortality Rates
According to a new Sheba study, COVID-19 patients with low free triiodothyronine levels could be at significantly higher risk of requiring mechanical ventilation and mortality.
Read More
Sheba Ranks on Newsweek’s Top Ten Hospitals in the World For the Third Consecutive Year
For the third consecutive year, we are delighted to learn that Sheba Medical Center has been named in Newsweek’s Top 10 Hospitals in the World.
Read More
One of the First Double Lung Transplants on a Recovering COVID-19 Patient was Successfully Completed at Sheba Medical Center
Complex Double Lung Transplant on a Recovering COVID-19 Patient Completed Successfully at Sheba Medical Center:
Read More
The World’s Leading Vaccination Drive Helps Bring Israel Closer to Normalcy
Israel Leads the World in Vaccinations and Hopes to Completely Reopen by the End of March. Click Here to Learn More.
Read More
New Chicago ARC Innovation Center
Chicago ARC Innovation Center is envisioned to connect the best science, talent, and technology to achieve health equity through a collaborative innovation platform
Read More
New Sheba Study Indicates that COVID-19 Infection Rates Are Significantly Reduced After a Single Dose of the Pfizer-BioNTech Vaccine
An 85% reduction in symptomatic COVID-19 infections among the recipients of the first dose of the Pfizer-BioNTech vaccine is indicated by new Sheba study. Learn more:
Read More
